此次科创板IPO，汉诺医疗拟募集资金10.62亿元，投向汉诺医疗研发中心建设项目、汉诺医疗生产基地 建设项目等4个项目。 招股书显示，汉诺医疗是一家具有全球竞争潜力的高端创新医疗器械企业，专注于体外生命支持 （ECLS）领域的技术创新，致力以前瞻性的医学工程技术向全世界提供稳定、可靠的循环支持与氧合 技术产品。 北京商报讯（记者 丁宁）12月23日晚间，上交所官网显示，深圳汉诺医疗科技股份有限公司（以下简 称"汉诺医疗"）科创板IPO获得受理。 ...

Core Insights - The A-share market has been significantly impacted by the recent IPOs of two GPU companies, Moore Threads and Muxi Co., which have set new records for profitability among new stocks in a short period [2] - The underwriting and sponsorship roles of securities firms have become increasingly important in this IPO frenzy, with major firms like CITIC Securities and Huatai United Securities benefiting substantially from these listings [2][5] Group 1: IPO Performance - Moore Threads' stock price surged to a peak of 688 CNY per share on its first trading day, resulting in a profit of up to 286,800 CNY for investors who received shares [2] - Muxi Co. subsequently raised this profit potential to 395,200 CNY, establishing a new record for A-share IPOs [2] - CITIC Securities, as the lead underwriter for Moore Threads, is estimated to earn around 1 billion CNY from underwriting fees and additional profits from stock holdings [5] Group 2: Underwriting and Sponsorship Earnings - The underwriting fees for Moore Threads included a sponsorship fee of 3 million CNY and a total underwriting fee of approximately 38.898 million CNY, with CITIC Securities expected to receive a significant portion [4][5] - Huatai United Securities, the lead underwriter for Muxi Co., is projected to earn about 267 million CNY in underwriting fees, alongside substantial profits from strategic placements [6][7] - Both firms have engaged in strategic placements and balance underwriting, which have contributed to their financial gains from these IPOs [6][8] Group 3: Market Trends and Regulatory Changes - The role of securities firms in the IPO process is evolving, with a shift towards competition for high-quality projects rather than merely the quantity of projects [7] - Recent regulatory changes by the China Securities Regulatory Commission aim to enhance the market-oriented issuance and underwriting mechanisms for the Sci-Tech Innovation Board [8] - As of December 23, several securities firms have participated in strategic placements, with total floating profits exceeding 4.5 billion CNY, indicating a trend towards concentrated resources among leading investment banks [8]

Group 1 - The core point of the article is that Yisiwei (Hangzhou) Technology Co., Ltd. has successfully registered its IPO on the Sci-Tech Innovation Board [1] - Yisiwei focuses on the research, production, and sales of machine vision equipment for automotive manufacturing, providing solutions for various processes in vehicle and component manufacturing [1] - The company aims to raise approximately 1.214 billion yuan through this IPO, which will be used for the industrialization of machine vision products, the establishment of a machine vision research and development center, and to supplement working capital [1] Group 2 - The IPO application was accepted on June 5, 2025, and the company entered the inquiry stage on June 27 of the same year [1] - Yisiwei received approval during the meeting on November 21, 2025, and submitted the registration on the same day [1]

北京商报讯(记者丁宁)12月22日晚间，上交所官网显示，苏州信诺维医药科技股份有限公司(以下简 称"信诺维")科创板IPO获得受理。 此次科创板IPO，信诺维拟募集资金不超29.4亿元，投向新药研发项目、补充流动资金。 据了解，信诺维符合并选择适用《上海证券交易所科创板股票上市规则》第2.1.2条第一款第(五)项规定 的上市标准。即预计市值不低于人民币40亿元，主要业务或产品需经国家有关部门批准，市场空间大， 目前已取得阶段性成果。医药行业企业需至少有一项核心产品获准开展二期临床试验，其他符合科创板 定位的企业需具备明显的技术优势并满足相应条件。 招股书显示，信诺维是一家聚焦于全球范围内重大未满足临床需求，以疾病为导向，致力于将创新转化 为临床价值，为患者提供疾病领域内最佳治疗药物的创新药公司，已形成"1(NDA)+3(III期)+N"的创新 药管线梯队，并通过全球BD授权或转让初步实现了以研养研。 ...

来源：钛媒体 12月24日，视涯科技股份有限公司（下称"视涯科技"）将科创板IPO上市，公开发行不超过10000万股。 笔者注意到，视涯科技营收未达科创板上市指标，且成立以来长期大额亏损，三年半累计亏超9亿元，研发投入几乎吞噬全部利润。更令人费解的是，公司 手握超15亿元现金类资产、偿债能力优于同行，却拟募资20.15亿元，合理性亟待解释。股权层面，视涯科技也出现了短期交易价差显著、上市前夕低价转 让股权、申报期代持未披露等问题。 股权定价混乱、代持未披露 视涯科技成立于2016年，由厦门晟山及厦门稷山出资设立，截至招股说明书签署日，顾铁通过直接以及间接的方式合计控制视涯科技61.79%的表决权，为 公司的实控人。 值得关注的是，在公司冲刺IPO的关键节点，股权变动频繁且浮现出多处令人费解的问题。据悉，2025年3月，顾浩与宁波视界、海宁艾克斯、联新三期及 上海箕山签订了股份转让协议，约定顾浩将其持有的公司968.0488 万股（对应1.08%股份）以人民币10,756.00万元的价格（对应11.11元/股）转让给宁波视 界、海宁艾克斯、联新三期及上海箕山。 同月，上海檀英与上海箕山签订了股份转让协议，约定上 ...

Core Viewpoint - The IPO journey of Beidou Institute has faced multiple challenges, with its current status being "inquired" and a significant increase in fundraising to 709 million yuan, alongside new investment projects [2][5] Group 1: IPO Details - Beidou Institute's IPO fundraising scale has increased from 416 million yuan in 2023 to 709 million yuan in the current attempt, with additional investment projects included [2][5] - The company has introduced 17 new institutional shareholders, including its largest customer, China Electronics Technology Group Corporation [2][8] Group 2: Financial Performance - From 2020 to 2025, Beidou Institute's revenue has shown fluctuations, with figures of 93.5 million yuan, 144 million yuan, 243 million yuan, 285 million yuan, and 325 million yuan respectively, while net profit has also increased but with a decline in net profit excluding non-recurring gains [6] - The gross profit margin has decreased from 75.35% in 2020 to 58.82% in the first half of 2025, indicating a narrowing profit space [6] Group 3: Client Concentration - In the first half of 2025, sales revenue from the top five customers accounted for 72.64% of total revenue, with China Electronics Technology Group being the largest customer and supplier [3][8] - The company has a high customer concentration, with significant sales to major clients, particularly in the defense and aerospace sectors [8][9] Group 4: Financial Health - As of June 2025, Beidou Institute held cash and cash equivalents of 459 million yuan, representing 42.74% of total assets, with a low debt ratio of 3.91% [3][9] - The company has a substantial amount of accounts receivable, which has been increasing, indicating a longer collection cycle due to the nature of its client base [9]

12月15日消息，近日被称为"国产GPU第一股"的摩尔线程，上市刚满一周，便抛出一则颇具冲击力的公 告。 12日晚间，摩尔线程宣布， 将拿出最高75亿元募集资金进行现金管理 。随后，消息迅速在市场发酵， 引发投资者与业内的高度关注。 国芯网[原:中国半导体论坛] 振兴国产半导体产业！ 不拘中国、 放眼世界 ！ 关注 世界半导体论坛 ↓ ↓ ↓ 从合规层面看，这一安排并不罕见。但问题在于时间节点 。摩尔线程于12月5日才刚刚登陆 科创板， 宣布现金管理之日 距离上市 刚满 一周。 另外值得注意的是 ， 摩尔线程以 88天过会、158天上市 的速度，成为 2022年以来审核最 快的科创板IPO ， 被不少媒体称为"跑出了科创板加速度"。而如今，"上市加速度"之后迅速 接上的，却是一则大额理财公告。 据悉，摩尔线程IPO计划募资80亿元，总募资79.996亿（募资净额75.76亿），此次拿出至高75亿理财， 占比亦超过9成。 12月12日晚间，摩尔线程发布公告称，公司及实施募投项目的子公司计划使用最高不超过75亿元（含本 数）的闲置募集资金进行现金管理，使用期限自董事会审议通过之日起12个月内有效。 公告显示， 投 ...

Core Viewpoint - Shiya Technology Co., Ltd. is undergoing a second round of inquiry for its IPO on the Sci-Tech Innovation Board, focusing on its technology, market position, clients, and operational performance [1] Group 1: Company Overview - Shiya Technology is a provider of micro-display overall solutions, with its core product being silicon-based OLED micro-displays [1] - The company offers value-added services including strategic product development, optical systems, and XR overall solutions [1] Group 2: IPO Details - The IPO was accepted on June 26, 2025, and entered the inquiry phase on July 21, 2025 [1] - Shiya Technology aims to raise approximately 2.015 billion yuan, which will be used for the expansion of ultra-high-resolution silicon-based OLED micro-display production lines and the construction of a research and development center [1]

Group 1 - The company has reported negative operating cash flow for two consecutive years, with a significant increase in accounts receivable by nearly 96%, and a drastic drop in collection rate to 42.77% [2][5] - Despite cash flow issues, the company distributed dividends totaling approximately 28 million yuan, raising questions about its financial management [6][7] - The company relies heavily on acquired patents, with over 85% of its patents being transferred, indicating potential concerns about its independent innovation capabilities [8][9] Group 2 - The company's revenue and net profit have shown a concerning trend, with a decrease in revenue by 1.86% and a net profit drop of 35.67% in the first half of 2025 compared to the previous year [3] - The company’s asset-liability ratio is relatively low at 24.11%, yet it continues to distribute dividends while seeking to raise funds through an IPO, which raises questions about its cash management strategy [7][8] - The company has faced multiple tax penalties, indicating potential compliance issues with tax regulations [16][17] Group 3 - The company’s military product pricing is subject to fluctuations due to a "provisional pricing settlement" model, which could lead to significant revenue adjustments based on final pricing determinations [12][15] - The company has a high dependency on a few major clients for sales, with over 57% of sales coming from the top five clients, which poses risks if any of these clients face adverse pricing adjustments [15] - The company’s R&D personnel make up only 11.67% of its workforce, barely meeting the minimum requirement for the Sci-Tech Innovation Board, raising concerns about its capacity for innovation [9][10]

Core Viewpoint - The company Tianomab is facing significant challenges as it attempts to go public on the STAR Market, with its core product's actual sales falling short of expectations, raising concerns about its financial viability and future growth prospects [1][3][4]. Group 1: Company Overview - Tianomab was established in 2015 and focuses on innovative biopharmaceuticals, particularly blood product alternatives [3]. - The company's core product, Staitodab monoclonal antibody injection (marketed as Xintimab), was approved for sale in China in February 2023 [3]. - As of the date of the report, Tianomab is in the process of conducting a Phase III clinical trial for another key product, TNM001 [3]. Group 2: Financial Performance - From 2022 to the first quarter of 2025, Tianomab has incurred cumulative losses of 1.567 billion yuan [5]. - The company has invested heavily in research and development, with total R&D expenses amounting to 1.275 billion yuan during the same period [5]. - Sales expenses during the reporting period totaled approximately 75.43 million yuan, despite only one product being commercialized by 2025 [5]. Group 3: Sales Performance - For the period from March to September, the expected sales for Staitodab were 56,800 units, but actual sales reached only 43,500 units, resulting in a completion rate of 76.67% for the self-operated team [4]. - External promotional teams had an even lower performance, with expected sales of 40,100 units but only achieving 2,600 units, leading to a completion rate of 6.42% [4]. - Overall, the combined expected sales were 96,900 units, while actual sales were only 46,100 units, resulting in a completion rate of 47.6% [4]. Group 4: Financial Liabilities and Risks - The company's current liabilities have been on the rise, with figures of 134 million yuan, 116 million yuan, and 285 million yuan reported, reaching 254 million yuan by the first quarter of 2025 [7]. - The liquidity ratios have significantly declined, with the current ratio dropping from 6.19 to 3.29 and the quick ratio from 6.02 to 3.06 [7]. - The company has a potential buyback obligation that could amount to several billion yuan if its IPO application is rejected, posing a substantial financial risk to the controlling shareholder [8].